TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Lepu Biopharma Co. Ltd. Class H ( (HK:2157) ) just unveiled an update.
Lepu Biopharma Co., Ltd. has announced an update regarding its New Drug Application (NDA) for MRG003, an ADC targeting EGFR for the treatment of recurrent or metastatic nasopharyngeal cancer. The company has voluntarily withdrawn its previous NDA to submit supplementary materials and plans to resubmit the application on March 4, 2025. This move aims to ensure a thorough review process and highlights the company’s commitment to advancing its drug candidate, although it may delay the approval timeline.
More about Lepu Biopharma Co. Ltd. Class H
Lepu Biopharma Co., Ltd. is a biopharmaceutical company based in China, focusing on the development of innovative oncology drugs. The company specializes in antibody drug conjugates (ADCs), with a particular emphasis on targeting epidermal growth factor receptor (EGFR) for the treatment of various cancers.
YTD Price Performance: 39.31%
Average Trading Volume: 9,789,968
Technical Sentiment Consensus Rating: Sell
Current Market Cap: HK$6.24B
For an in-depth examination of 2157 stock, go to TipRanks’ Stock Analysis page.